Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001

NCT01369225 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01369225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01369225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Extension, Multiple Dose, Parallel Group Study To Investigate The Long-term Safety And Tolerability Of Aab-003 (Pf-05236812) Administered Intravenously In Subjects With Mild To Moderate Alzheimer's Disease Previously Treated With Aab-003 Or Placebo In Protocol B2601001
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2011
Completion date
August 31, 2014
Enrollment
52 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease